Inloggen
Inloggen
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registreer
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepagina
  2. Aandelen
  3. Canada
  4. Bourse de Toronto
  5. Rakovina Therapeutics Inc.
  6. Nieuws
  7. Andere talen
    RKV   CA75103L1013

RAKOVINA THERAPEUTICS INC.

(RKV)
Vertraagde tijd Bourse de Toronto  -  21:49 23-09-2022
0.1850 CAD   +8.82%
11/08Rakovina Therapeutics Verlies in tweede kwartaal daalt door lagere uitgaven
MT
10/08Rakovina Therapeutics Inc. Rapporteert Winstresultaten voor het Tweede Kwartaal en de Zes Maanden Geëindigd op 30 Juni, 2022
CI
25/05Rakovina Therapeutics Inc. Rapporteert Winstresultaten voor het Eerste Kwartaal Geëindigd op 31 Maart, 2022
CI
OverzichtKoersenGrafiekenNieuwsAgendaOndernemingFinanciŽnBeursproductenFonds 
OverzichtAl het nieuwsAndere talenPersberichtenOfficiŽle publicatiesSectornieuws
Nieuws in andere talen op RAKOVINA THERAPEUTICS INC.
11/08Rakovina Therapeutics Second-Quarter Loss Narrows on Lower Spending
11/08Rakovina Therapeutics Inc. Announces Q2 2022 Financial Results and Provides Corporate U..
11/08Rakovina Therapeutics Inc. Announces Q2 2022 Financial Results and Provides Corporate U..
10/08Rakovina Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Mont..
24/06Rakovina Therapeutics Announces Results from Annual General Meeting
24/06Rakovina Therapeutics Announces Results from Annual General Meeting
27/05RAKOVINA THERAPEUTICS : Transform & Extend the Lives of Patients with Cancer, CEO Clip Vid..
26/05Rakovina Therapeutics Inc. Announces Q1 2022 Financial Results and Provides Corporate U..
25/05Rakovina Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 3..
11/05Rakovina Therapeutics Presents Preclinical Data on its Novel kt-3000 Series at the 2022..
11/05Rakovina Therapeutics Presents Preclinical Data on its Novel kt-3000 Series at the 2022..
11/05Rakovina Therapeutics Presents Preclinical Data on its Novel kt-3000 Series at the 2022..
27/04Rakovina Therapeutics Reports Q4 Net Loss of $751K
27/04Rakovina Therapeutics Inc. Announces 2021 Financial Results and Provides Corporate Upda..
26/04Rakovina Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31..
12/04Rakovina Therapeutics Presents Preclinical Data For kt-4000 Series Compounds at AACR An..
12/04Rakovina Therapeutics Presents Evaluation of A Novel Class of Bifunctional DNA Alkylati..
12/04Rakovina Therapeutics Presents Preclinical Data Supporting Potential Broad Anticancer A..
30/03Rakovina Therapeutics to Present Abstract at the 2022 AACR Special Conference – S..
30/03Rakovina Therapeutics to Present Abstract at the 2022 AACR Special Conference – S..
09/03Rakovina Therapeutics to Present Abstract at Annual Meeting of the American Association..
09/03Rakovina Therapeutics to Present Abstract at the 2022 Annual Meeting of the American As..
09/03Rakovina Therapeutics to Present Abstract at the 2022 Annual Meeting of the American As..
25/01Rakovina Therapeutics President to Join Expert Panel at the Fifth Annual DDR, ATR & PAR..
06/01Rakovina Therapeutics Inc. to Present at Biotech Showcase 2022
2021Rakovina Therapeutics Announces Financial Contributions to Support Lead Optimization of..
2021Rakovina Therapeutics Inc. Announces Non-Dilutive Financial Contributions to Support Le..
2021Rakovina Therapeutics Announces Non-dilutive Financial Contributions to Support Lead Op..
2021Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing
2021Rakovina Therapeutics Inc. Announces Third Quarter 2021 Financial Results and Provides ..
2021Rakovina Therapeutics Inc. Announces the Transition of Julie Cherrington from the Board..
2021Rakovina Therapeutics Partners with St. Baldrick's Foundation to Research and Develop N..
2021Rakovina Therapeutics Partners with St. Baldrick?s Foundation to Research and Develop N..
2021Rakovina Therapeutics Presents at the 6th biennial Canadian Cancer Research Conference
2021Rakovina Therapeutics Inc. Presents At the 6Th Biennial Canadian Cancer Research Confer..
2021RAKOVINA THERAPEUTICS : to Present at the 6 th biennial Canadian Cancer Research Conferenc..
2021RAKOVINA THERAPEUTICS : to Present at the 6th biennial Canadian Cancer Research Conference
2021RAKOVINA THERAPEUTICS : Presents at the 2021 AACRNCI-EORTC Virtual International Conferenc..
2021RAKOVINA THERAPEUTICS : Presents at the 2021 AACR-NCI-EORTC Virtual International Conferen..
2021Rakovina Therapeutics Presents at the 2021 AACR-NCI-EORTC Virtual International Confere..
2021RAKOVINA THERAPEUTICS : Receives Notice of Allowance for New U.S. Patent
2021RAKOVINA THERAPEUTICS INC : . Receives Notice of Allowance for New U.S. Patent Covering kt..
2021Rakovina Therapeutics Inc. Receives Notice of Allowance for New U.S. Patent Covering KT..
2021RAKOVINA THERAPEUTICS : Presents Preclinical Data on kt-3000 Series Drug Candidates at JCA..
2021RAKOVINA THERAPEUTICS : Presents Preclinical Data on novel kt-3000 Series Drug Candidates ..
2021Rakovina Therapeutics Presents Preclinical Data on Novel kt-3000 Series Drug Candidates..
2021RAKOVINA THERAPEUTICS : to Present at the JCA-AACR Precision Medicine International Confer..
2021RAKOVINA THERAPEUTICS INC : . Announces Second Quarter 2021 Financial Results and Provides..
2021Rakovina Therapeutics Inc. Reports Earnings Results for the Second Quarter Ending June ..
2021RAKOVINA THERAPEUTICS : to Present at the AACR-NCI-EORTC International Conference on Molec..
2021RAKOVINA THERAPEUTICS : Red Thread Ventures' portfolio company Rakovina Therapeutics'
2021RAKOVINA THERAPEUTICS : Announces Results from Annual General Meeting
2021RAKOVINA THERAPEUTICS : to Present at at The Emerging Growth Conference on June 23, 2021
2021RAKOVINA THERAPEUTICS INC : . Announces First Quarter 2021 Financial Results and Provides ..
2021Rakovina Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 3..
2021Rakovina Therapeutics Inc. Announces Inaugural Scientific Advisory Board
2021RAKOVINA THERAPEUTICS INC : . Announces Inaugural Scientific Advisory Board
2021RAKOVINA THERAPEUTICS INC : . Receives European and Canadian Patents on kt-2000 series PAR..
2021Rakovina Therapeutics Inc. Receives European and Canadian Patents on kt-2000 series PAR..
2021Rakovina Therapeutics Inc. Appoints Julie M. Cherrington, Phd to Board of Directors
2021Rakovina Therapeutics Inc. Announces Board Appointments
2021Rakovina Therapeutics Inc. announced that it has received CAD 4.5659 million in funding
2021CERTAIN WORLDWIDE RIGHTS OF NEWGEN T : VCO.P) in a reverse merger transaction.
2021Rakovina Therapeutics Inc. Auditor Raises 'Going Concern' Doubt
2020Rakovina Therapeutics Inc. Enters into an Agreement with the University of British Colu..
2020Rakovina Therapeutics Inc. announced that it expects to receive CAD 2.5 million in fund..
2020CERTAIN WORLDWIDE RIGHTS OF NEWGEN T : VCO.P) in a reverse merger transaction for CAD 6 mi..
Volgende evenement op RAKOVINA THERAPEUTICS INC.